1. FRI0322 Rationale for the atacicept dose for a phase iii study in patients with highly active and auto-antibody positive sle. (12th June 2018) Authors: Shen, J.; Papasouliotis, O.; Samy, E.; Haselmayer, P.; Chang, P.; Ona, V.; Kao, A. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 697 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Long-term efficacy and safety of intra-articular sprifermin in patients with knee osteoarthritis: results from the 5-year forward study. Issue 1 (April 2020) Authors: Eckstein, F.; Hochberg, M.; Kraines, J.; Guehring, H.; Moreau, F.; Ona, V.; Bihlet, A.R.; Byrjalsen, I.; Andersen, J.R.; Daelken, B.; Guenther, O.; Ladel, C.; Michaelis, M.; Conaghan, P.G. Journal: Osteoarthritis and cartilage Issue: Volume 28:Issue 1(2020)supplement Page Start: S77 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗